[go: up one dir, main page]

BRPI0607680A2 - agente profilático/terapêutico para anormalidades do metabolismo de açúcar/lipìdio - Google Patents

agente profilático/terapêutico para anormalidades do metabolismo de açúcar/lipìdio

Info

Publication number
BRPI0607680A2
BRPI0607680A2 BRPI0607680-7A BRPI0607680A BRPI0607680A2 BR PI0607680 A2 BRPI0607680 A2 BR PI0607680A2 BR PI0607680 A BRPI0607680 A BR PI0607680A BR PI0607680 A2 BRPI0607680 A2 BR PI0607680A2
Authority
BR
Brazil
Prior art keywords
lipid metabolism
prophylactic
sugar
therapeutic agent
metabolism abnormalities
Prior art date
Application number
BRPI0607680-7A
Other languages
English (en)
Inventor
Yuji Abe
Aki Kusunoki
Yoshiharu Hayashi
Fumihiko Akahoshi
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of BRPI0607680A2 publication Critical patent/BRPI0607680A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

AGENTE PROFILáTICO/TERAPêUTICO PARA ANORMALIDADES DO METABOLISMO DE AçúCAR/LIPIDIO. A presente invenção refere-se a um agente farmacêutico para o tratamento e/ou profilaxia de metabolismo anormal de glicose e lipídio no sangue associado às refeições, para o qual um método de tratamento suficiente ou um fármaco terapêutico não foi descoberto.
BRPI0607680-7A 2005-04-26 2006-04-26 agente profilático/terapêutico para anormalidades do metabolismo de açúcar/lipìdio BRPI0607680A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005127523 2005-04-26
PCT/JP2006/308695 WO2006118127A1 (ja) 2005-04-26 2006-04-26 糖・脂質代謝異常の予防及び/又は治療薬

Publications (1)

Publication Number Publication Date
BRPI0607680A2 true BRPI0607680A2 (pt) 2009-09-22

Family

ID=37307926

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607680-7A BRPI0607680A2 (pt) 2005-04-26 2006-04-26 agente profilático/terapêutico para anormalidades do metabolismo de açúcar/lipìdio

Country Status (12)

Country Link
US (2) US20090088442A1 (pt)
EP (1) EP1882474B1 (pt)
JP (1) JP5100375B2 (pt)
KR (1) KR101333876B1 (pt)
CN (1) CN101175494B (pt)
AT (1) ATE486604T1 (pt)
BR (1) BRPI0607680A2 (pt)
CA (1) CA2605847C (pt)
DE (1) DE602006017997D1 (pt)
ES (1) ES2355156T3 (pt)
MX (1) MX2007013301A (pt)
WO (1) WO2006118127A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101352650B1 (ko) 2005-02-18 2014-01-16 미쓰비시 타나베 파마 코퍼레이션 프롤린 유도체의 염 또는 그 용매화물 및 그 제조 방법
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20110190322A1 (en) 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
EA029759B1 (ru) 2009-02-13 2018-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
KR102328772B1 (ko) 2009-11-27 2021-11-19 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US9572806B2 (en) * 2009-12-18 2017-02-21 Mitsubishi Tanabe Pharma Corporation Elution-stabilized preparation
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006899A1 (en) * 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
EP1308439B1 (en) * 2000-08-10 2008-10-15 Mitsubishi Tanabe Pharma Corporation Proline derivatives and use thereof as drugs
US20040180925A1 (en) * 2000-12-27 2004-09-16 Kenji Matsuno Dipeptidylpeptidase-IV inhibitor
CZ20032321A3 (en) * 2001-02-02 2004-03-17 Takeda Chemical Industries, Ltd. Fused heterocyclic compounds
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
US6710040B1 (en) * 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
BR0311608A (pt) 2002-06-04 2005-02-22 Pfizer Prod Inc Amidas cìclicas fluoradas como inibidores da dipeptidil-peptidase iv
US6995183B2 (en) * 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
KR101352650B1 (ko) * 2005-02-18 2014-01-16 미쓰비시 타나베 파마 코퍼레이션 프롤린 유도체의 염 또는 그 용매화물 및 그 제조 방법

Also Published As

Publication number Publication date
WO2006118127A1 (ja) 2006-11-09
MX2007013301A (es) 2008-03-07
JP5100375B2 (ja) 2012-12-19
ATE486604T1 (de) 2010-11-15
EP1882474B1 (en) 2010-11-03
EP1882474A1 (en) 2008-01-30
EP1882474A4 (en) 2008-07-09
US20090088442A1 (en) 2009-04-02
CA2605847C (en) 2014-02-04
KR20080010436A (ko) 2008-01-30
CN101175494A (zh) 2008-05-07
US20100305139A1 (en) 2010-12-02
ES2355156T3 (es) 2011-03-23
JPWO2006118127A1 (ja) 2008-12-18
KR101333876B1 (ko) 2013-11-27
CA2605847A1 (en) 2006-11-09
DE602006017997D1 (de) 2010-12-16
CN101175494B (zh) 2011-07-13

Similar Documents

Publication Publication Date Title
BRPI0607680A2 (pt) agente profilático/terapêutico para anormalidades do metabolismo de açúcar/lipìdio
EP2322219A3 (en) Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
EP2036574A4 (en) MEDICAL AGENT FOR THE TREATMENT OF FAT, DIABETES AND DISEASES IN CONNECTION WITH IMPROVED GLUCOSE TOLERANCE
BRPI0814957A2 (pt) Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.
ITMI20041317A1 (it) Formulazioni farmaceutiche per la somministrazione sicura di farmaci utilizzati nel trattamento della tossicodipendenza e procedimento per il loro ottenimento
EA200802208A1 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
SE0303571D0 (sv) Medical product for moisture-sensitive medicaments
UA100111C2 (ru) Лечение диабета типа 2 комбинацией ингибитора dpiv и метформина или тиазолидиндиона
TW200740452A (en) Therapeutic gastrodia extracts
WO2008149802A1 (ja) アンドログラホリドを有効成分とする抗疲労剤及び経口組成物
WO2008060362A3 (en) Methods and compositions for the treatment of skin diseases and disorders
WO2008148573A3 (de) Arzeimittel mit einer wirkstoffkombination enthaltend pantothensäure oder deren derivate zur behandlung von allergischen symptomen
BRPI0610780A2 (pt) formulação farmacéutica em tablete desintegrante, e, métodos para tratar um paciente em necessidade de tratamento com olanzapina, e para produzir a formulação farmacêutica em tablete
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2008155390A3 (en) Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases.
NO20080037L (no) Kombinasjon av pyrimidylaminobenzamidforbindelser og imatinib for behandling eller forbyggelse av proliferative sykdommer
WO2006131651A3 (fr) Composition a base d'une avermectine et d’ηydrocortisone notamment pour le traitement de la rosacée
IL191365A0 (en) A preparation for use in the case of diseases of the metabolism of blood, including diabetes
SE0401568D0 (sv) A lock solution for medical devices, a device and a method for the application thereof
WO2008101724A8 (en) Use of riboflavin in the treatment of hypertension
WO2006002846A3 (en) New analogs of nitrobenzylthioinosine
NO20074767L (no) Anvendelse av rimonabant for fremstilling av medikamenter som kan anvendes i forebygging og behandling av type 2 diabetes
WO2007054566A3 (en) Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy
UA92908C2 (ru) Соединения, производные от 5-тиоксилозы, и их терапевтическое применение

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.